ABUS (Arbutus Biopharma) Total Liabilities: $17.0 Mil (As of Mar. 2026)

What is Arbutus Biopharma Total Liabilities?

Arbutus Biopharma ABUS +3.74% 51 Total Liabilities is $17.0 Mil as of Mar. 2026. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $51.39 (Possible Value Trap). The stock has 5 warning signs investors should review.

Arbutus Biopharma's Total Liabilities for the quarter that ended in Mar. 2026 was $17.0 Mil.

Arbutus Biopharma's quarterly Total Liabilities declined from Sep. 2025 ($20.31 Mil) to Dec. 2025 ($18.04 Mil) and declined from Dec. 2025 ($18.04 Mil) to Mar. 2026 ($16.99 Mil).

Arbutus Biopharma's annual Total Liabilities declined from Dec. 2023 ($38.38 Mil) to Dec. 2024 ($34.34 Mil) and declined from Dec. 2024 ($34.34 Mil) to Dec. 2025 ($18.04 Mil).

Arbutus Biopharma Total Liabilities Related Terms

Arbutus Biopharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Total Liabilities Chart

Arbutus Biopharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

35.05

58.57

38.38

34.34

18.04

Arbutus Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															37.85	20.29	20.31	18.04	16.99

51GF Score

Arbutus Biopharma Corp ABUS

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Arbutus Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Arbutus Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6.006	+	(0.199	+	11.837
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	18.0

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	94.618	-	76.576
	=	18.0

Arbutus Biopharma's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	5.105	+	(0	+	11.882
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	17.0

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	277.164	-	260.177
	=	17.0

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $17.0 Mil mean?

Arbutus Biopharma (ABUS) has a Total Liabilities of $17.0 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Arbutus Biopharma and its competitors.

Is Arbutus Biopharma's Total Liabilities too high?

Arbutus Biopharma's current Total Liabilities is $17.0 Mil. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Arbutus Biopharma's Total Liabilities compare to SPRY and KURA?

Arbutus Biopharma's Total Liabilities of $17.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Arbutus Biopharma and its competitors. Arbutus Biopharma's current Total Liabilities is $17.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Arbutus Biopharma stock overvalued right now?

Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.39, compared to a current price of $4.57 — trading 91.1% below its estimated fair value. The current Total Liabilities is $17.0 Mil. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Total Liabilities is $17.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.57 is trading 91.1% below its estimated GF Value™ of $51.39. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

Total Liabilities: $17.0 Mil
GF Value™: $51.39 vs. price of $4.57 (91.1% below fair value)
GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies SPRY KURA JANX ANNX SANA XNCR ORIC AVTX SPTX EVMN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges I9DN:Germany

Address 701 Veterans Circle, Warminster, PA, USA, 18974

Website http://www.arbutusbio.com

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

51GF Score

Get the complete analysis for ABUS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.57

Price

$51.39

GF Value

View ABUS Analysis

See Total Liabilities data for all stocks →